Get started
Author

Sivan Gazit

Observed names: Gazit Sivan, Gazit, Sivan, S Gazit, S. Gazit
Observed institutions: Ben-Gurion University of the Negev, Tel Aviv University, Maccabi Healthcare Services, Maccabi Institute for Health Services Research, Massachusetts Institute of Technology, Stanford University
ORCID: 0000-0001-9875-3550
Observed ORCID: 0000-0001-9875-3550
OpenAlex ID: A5034265331
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
2021 · Matan Levine-Tiefenbrun, Idan Yelin, et al. · Nature Medicine · 515
PDF
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study
2022 · Sivan Gazit, Roei Shlezinger, et al. · Clinical Infectious Diseases · 283
PDF
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
2021 · Barak Mizrahi, Roni Lotan, et al. · Nature Communications · 261
PDF
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
2021 · Matan Levine-Tiefenbrun, Idan Yelin, et al. · Nature Medicine · 222
PDF
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
2021 · Gabriel Chodick, Lilac Tene, et al. · JAMA Network Open · 181
PDF
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
2021 · Gabriel Chodick, Lilac Tene, et al. · Clinical Infectious Diseases · 176
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
2022 · Ottavia Prunas, Joshua L. Warren, et al. · Science · 153
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
2022 · Tal Patalon, Yaki Saciuk, et al. · Nature Communications · 143
PDF
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
2021 · Tal Patalon, Sivan Gazit, et al. · JAMA Internal Medicine · 141
PDF
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
2021 · Oren Milman, Idan Yelin, et al. · Nature Medicine · 109
PDF
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
2022 · Sivan Gazit, Yaki Saciuk, et al. · BMJ · 87
PDF
Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities
2021 · Idan Yelin, Rachel Katz, et al. · medRxiv · 72
PDF
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
2022 · Matan Levine-Tiefenbrun, Idan Yelin, et al. · Nature Communications · 63
PDF
The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine
2022 · Sivan Gazit, Roei Shlezinger, et al. · Annals of Internal Medicine · 56
Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study
2022 · Noga Fallach, Yaakov Segal, et al. · PLoS ONE · 55
PDF
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
2022 · Matan Yechezkel, Merav Mofaz, et al. · The Lancet Respiratory Medicine · 37
Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study
2022 · Limor Adler, Sivan Gazit, et al. · Scandinavian Journal of Primary Health Care · 37
BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign
2021 · Amir Ben-Tov, Tamar Banon, et al. · Gastroenterology · 37
PDF
Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
2021 · Daniel Grupel, Sivan Gazit, et al. · Vaccine · 35
PDF
Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
2022 · Merav Mofaz, Matan Yechezkel, et al. · Emerging infectious diseases · 30
PDF
An Outbreak of Parvovirus B19 in Israel
2023 · Tal Patalon, Yaki Saciuk, et al. · Viruses · 27
PDF
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
2023 · Sivan Gazit, Yaki Saciuk, et al. · The Lancet Microbe · 26
PDF
A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report
2021 · Galit Perez, Tamar Banon, et al. · medRxiv · 25
PDF
BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure: Analysis of Household Members of Coronavirus Disease 2019 Patients
2021 · Sivan Gazit, Barak Mizrahi, et al. · Clinical Infectious Diseases · 24
PDF
Survey of Behaviour Attitudes Towards Preventive Measures Following COVID-19 Vaccination
2021 · Daniella Rahamim-Cohen, Sivan Gazit, et al. · medRxiv · 24
PDF
Works count: 120
Citation count: 3,066
H-index: 24
I10-index: 34
Year
Topic
Type